QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Meyers, C. A. Articles by Hess, K. R. Search for Related Content PubMed PubMed Citation

Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression

Departments of Neuro-Oncology (C.A.M.) and Biostatistics (K.R.H.), The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

¹ Address correspondence and reprint requests to Christina A. Meyers, Department of Neuro-Oncology, Box 431, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 (cameyers{at}mdanderson.org).

Abstract

Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression.We evaluated 56 patients with recurrent brain tumors who were recruited on phase 1 and phase 2 clinical trials and given assessments of cognitive function, quality of life (QOL), and ability to perform activities of daily living (ADL) prior to receiving treatment and at intervals coinciding with MRI scans, generally monthly. Meaningful change on the cognitive and functional assessments was determined by the reliable change index. Cognitive or functional deterioration was then used as a time-dependent covariate in a Cox proportional hazards regression model with tumor progression, as defined by standard criteria, as the end point. Cognitive deterioration occurred 6 weeks prior to radiographic failure (median 7.4 weeks vs. 13.4 weeks). In contrast, median time for QOL to deteriorate was not achieved. Median time for instrumental ADL to decline was 43 weeks, long after tumor progression. For patients with brain cancer, brain function began to worsen before MRI evidence of tumor progression. QOL and ADL function were not strongly tied to cognitive decline or to time to tumor progression, suggesting that these measures may not be sufficiently sensitive to change in clinical trials of new anticancer agents, although they are important measures in terms of patient care. This study also demonstrates the feasibility of performing neurocognitive testing in this patient population. New drugs that slow the cognitive decline of brain tumor patients may be of clinical benefit regardless of the impact on overall survival.

This article has been cited by other articles:

				I. Bosma, M. J. Vos, J. J. Heimans, M. J.B. Taphoorn, N. K. Aaronson, T. J. Postma, H. M. van der Ploeg, M. Muller, W. P. Vandertop, Ben. J. Slotman, et al. The course of neurocognitive functioning in high-grade glioma patients Neuro-oncol, January 1, 2007; 9(1): 53 - 62. [Abstract] [Full Text] [PDF]

				P. D. Brown, A. W. Jensen, S. J. Felten, K. V. Ballman, P. L. Schaefer, K. A. Jaeckle, J. H. Cerhan, and J. C. Buckner Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma J. Clin. Oncol., December 1, 2006; 24(34): 5427 - 5433. [Abstract] [Full Text] [PDF]

				M. R. Gilbert and F. F. Lang Anaplastic Oligodendroglial Tumors: A Tale of Two Trials J. Clin. Oncol., June 20, 2006; 24(18): 2689 - 2690. [Full Text] [PDF]

				E. G. Shaw, R. Rosdhal, R. B. D'Agostino Jr, J. Lovato, M. J. Naughton, M. E. Robbins, and S. R. Rapp Phase II Study of Donepezil in Irradiated Brain Tumor Patients: Effect on Cognitive Function, Mood, and Quality of Life J. Clin. Oncol., March 20, 2006; 24(9): 1415 - 1420. [Abstract] [Full Text] [PDF]

				D. Khuntia, P. Brown, J. Li, and M. P. Mehta Whole-Brain Radiotherapy in the Management of Brain Metastasis J. Clin. Oncol., March 10, 2006; 24(8): 1295 - 1304. [Abstract] [Full Text] [PDF]

				C. A. Meyers and P. D. Brown Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors J. Clin. Oncol., March 10, 2006; 24(8): 1305 - 1309. [Abstract] [Full Text] [PDF]

				M. Klein, T.J. Postma, M.J.B. Taphoorn, N.K. Aaronson, W.P. Vandertop, M. Muller, H.M. van der Ploeg, and J.J. Heimans The prognostic value of cognitive functioning in the survival of patients with high-grade glioma Neurology, December 23, 2003; 61(12): 1796 - 1798. [Abstract] [Full Text] [PDF]

				C. A. Meyers and J. S. Wefel The Use of the Mini-Mental State Examination to Assess Cognitive Functioning in Cancer Trials: No Ifs, Ands, Buts, or Sensitivity J. Clin. Oncol., October 1, 2003; 21(19): 3557 - 3558. [Full Text] [PDF]